5 results on '"Josef R. Patsch"'
Search Results
2. [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)]
- Author
-
Bernhard, Föger and Josef R, Patsch
- Subjects
Male ,Private Practice ,Hyperlipidemias ,Cholesterol, LDL ,Comorbidity ,Coronary Artery Disease ,Atherosclerosis ,Risk Assessment ,Hospitalization ,Treatment Outcome ,Risk Factors ,Austria ,Diabetes Mellitus ,Prevalence ,Secondary Prevention ,Humans ,Female ,Aged ,Hypolipidemic Agents - Abstract
A hospital-based screening project (HSP) in Austria found 47% of high-risk patients (LDL-C100 mg/dl) and 24% of very high-risk patients (LDL-C70 mg/dl) at goal. Separate data for the sexes were not reported. We analyze whether LDL-C goal attainment in patients with manifest atherosclerosis and/or diabetes on stable lipid-lowering treatment differs between private practice and hospital and between men and women.From September to November 2007, 49 Austrian centers (36 private practice, 13 hospitals) documented vascular morbidity, lipid levels, and lipid lowering treatment in patients with high risk (atherosclerosis or diabetes, n = 978) and very high risk (coronary heart disease and diabetes or acute coronary syndrome, n = 322).75% and 25% of the 1300 patients were high and very high risk, respectively. LDL-C goals of100 and70 mg/dl, respectively, were attained by 45.4% and 26.4% of patients (p0.001). A similar percentage of patients with very high risk was found in men and women (26.4% vs. 22.9%, NS) and goal attainment was not influenced by sex (high risk: 47.2% (m) vs. 43.8% (w), NS and very high risk: 29.1% (m) vs. 22.4% (w), NS). In patients with high risk, 41.6% treated in private practice vs. 57.9% treated in the hospital were at goal (p0.001). In patients with very high risk, 15.9% treated in private practice vs. 45.2% treated in the hospital were at goal (p0.001). Lower goal-attainment in private practice occurred despite significantly more intensive lipid intervention and probably reflects higher baseline LDL-C. LDL-C100 mg/dl leads to a more aggressive lipid lowering in approx. 70% of patients, irrespective of whether they are treated in private practice or in the hospital. LDL-C between 70 and 100 mg/dl, however, leads to a more aggressive lipid lowering in5% of patients, irrespective of whether they are high or very high risk.As observed in EUROASPIRE III for other European countries, there is substantial potential for improvement in lipid control in Austrian cardiovascular high-risk patients, irrespective of whether they are treated in private practice or in the hospital. more...
- Published
- 2010
Catalog
3. Analysis of long-chain omega-3 fatty acid content in fish-oil supplements
- Author
-
Karin Salzmann, Markus Laimer, Susanne Kaser, Tobias Tatarczyk, Christian Ciardi, Julia Engl, Josef R. Patsch, Christoph Ebenbichler, and Ruth Lenners
- Subjects
chemistry.chemical_classification ,Chromatography, Gas ,business.industry ,Hypertriglyceridemia ,Fatty acid ,Arrhythmias, Cardiac ,Hyperlipidemias ,General Medicine ,Fish oil ,medicine.disease ,Atherosclerosis ,Capillary gas chromatography ,chemistry ,Western diet ,Dietary Supplements ,Fatty Acids, Omega-3 ,medicine ,Humans ,Fatty acid composition ,Food science ,business ,Long chain ,Polyunsaturated fatty acid - Abstract
BACKGROUND: Omega-3 polyunsaturated fatty acids (long-chain ω-3 PUFA) have proved to be beneficial in atherosclerosis, arrhythmia and hypertriglyceridemia in several studies, which has led national and international societies to recommend an intake of 1 g/d long-chain ω-3 PUFA for antiatherosclerotic and antiarrhythmic purposes or 2–4 g/d for a lipid lowering effect. Numerous preparations are marketed for supplementing western diet, which is low in long-chain ω-3 PUFA. Since these preparations vary in their long-chain ω-3 PUFA content, we tested nine commercially available products for their fatty acid composition. METHODS: Nine commercially available ω-3 fatty acid supplements were analyzed using capillary gas chromatography to determine their fatty acid content. RESULTS: The nine preparations showed huge differences, up to 63.7 ± 1.58 mol% (P = 0.002), in their longchain ω-3 fatty acid content. Most of them failed to achieve the daily recommended dose of 1 g, even when administered at the highest dosage according to the manufacturer's recommendations. Eight of the preparations contained either equal or significantly greater amounts of long-chain ω-3 PUFA than denoted by the manufacturer; one preparation did not provide any information. The highest percentage of DHA and EPA was detected in Omacor® (95.80 ± 0.63%) and Percucor® (76.8 ± 7.109%). CONCLUSION: Administering long-chain ω-3 fatty acid preparations may result in huge differences in terms of the actual amount ingested. It is therefore advisable to use the most standardized and purified products available. more...
- Published
- 2006
4. [Antipsychotic drug-induced changes in metabolism]
- Author
-
Christoph Ebenbichler, Maria Rettenbacher, Josef R. Patsch, Alexander Tschoner, Markus Laimer, Julia Engl, and W. Wolfgang Fleischhacker
- Subjects
Gynecology ,medicine.medical_specialty ,Clinical Trials as Topic ,Metabolic Diseases ,Psychotic Disorders ,business.industry ,Risk Factors ,Medicine ,Humans ,General Medicine ,business ,Risk Assessment ,Antipsychotic Agents - Abstract
Antipsychotika der neuen Generation verdrangen vermehrt die klassischen Antipsychotika, vor allem wegen des geringeren Risikos Nebenwirkungen des extrapyramidalmotorischen Systems hervorzurufen und aufgrund einiger therapeutischer Vorteile. Die Verwendung der Antipsychotika der neuen Generation wird jedoch vermehrt mit starker Gewichtszunahme, der Induktion einer Insulinresistenz und eines atherogenen Lipidprofils assoziiert. Unter diesen Substanzen fuhren Clozapin und Olanzapin zur starksten Gewichtszunahme, hauptsachlich uber eine Vermehrung des Korperfettes, und zu Veranderungen der Glukosehomoostase. In den meisten Fallen trat ein Diabetes mellitus bereits innerhalb von Tagen bis Wochen nach Therapiebeginn mit diesen Antipsychotika auf, in den meisten Fallen waren die neu aufgetretenen Storungen der Glukosehomoostase nach Absetzen der Medikation reversibel und einige Berichte beschreiben ein erneutes Auftreten bei neuerlicher Behandlung mit derselben Medikation. Ein moglicher Pathomechanismus fur die Entstehung einer Hyperglykamie unter Therapie mit Antipsychotika der neuen Generation stellt die Beeintrachtigung der Insulinwirkung uber humorale und/oder zellulare Mechanismen dar. Alternativ konnte ein durch Antipsychotika induzierter Diabetes mellitus sekundar durch eine Gewichtszunahme entstehen oder infolge einer Veranderung der Fettverteilung, insbesondere einer Vermehrung der viszeralen Fettdepots, oder durch eine direkte Wirkung an insulinsensitiven Geweben. In diesem Artikel geben wir einen Uberblick uber die metabolischen Nebenwirkungen unter der Therapie mit Antipsychotika der neuen Generation, versuchen den Pathomechanismus dieser Nebenwirkungen zu beleuchten und mochten mogliche zukunftige Therapieansatze darstellen und diskutieren. more...
- Published
- 2006
5. [The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery]
- Author
-
Julia Engl, Christoph Ebenbichler, Ursula Hanusch-Enserer, Rudolf Prager, and Josef R. Patsch
- Subjects
Male ,medicine.medical_specialty ,Bariatrics ,Gastroplasty ,Cost effectiveness ,Cost-Benefit Analysis ,Population ,Gastric Bypass ,World Health Organization ,Body Mass Index ,Insulin resistance ,Lipectomy ,Weight loss ,Risk Factors ,Diabetes mellitus ,Weight Loss ,medicine ,Prevalence ,Homeostasis ,Humans ,Obesity ,education ,Life Style ,Ultrasonography ,Metabolic Syndrome ,education.field_of_study ,Clinical Trials as Topic ,business.industry ,General Medicine ,medicine.disease ,Biliopancreatic Diversion ,Magnetic Resonance Imaging ,Surgery ,Glucose ,Quality of Life ,Female ,Endothelium, Vascular ,medicine.symptom ,Metabolic syndrome ,business ,Tomography, X-Ray Computed ,Forecasting - Abstract
The prevalence of obesity is rising worldwide dramatically, affecting up to 50 percent of the population. The epidemic of obesity leads to a marked increase in the metabolic syndrome, a cluster of cardiovascular risk factors characterized by visceral obesity, insulin resistance, low HDL-Cholesterol, hypertriglyceridemia, and a subclinical proinflammatory state. In the last years, the NCEP and the WHO highlighted and defined the key features of the metabolic syndrome to facilitate the clinical diagnosis and preventive interventions. The conservative therapy of obesity and the metabolic syndrome by life style intervention and pharmacological interventions leads only to moderate weight loss with inconstant long-term success. Intervention by bariatric surgery can serve as a model for the metabolic effects of permanent weight loss. In several studies the pronounced weight loss induced a reduction of almost all components of the metabolic syndrome, including glucose and lipid status and is followed by an improvement in the quality of life. Recent research suggested a decrease in mortality rate in addition to cost effectiveness of bariatric surgery. more...
- Published
- 2005
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.